Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1994 6
1995 15
1996 44
1997 84
1998 165
1999 257
2000 273
2001 344
2002 384
2003 472
2004 488
2005 529
2006 601
2007 543
2008 583
2009 471
2010 508
2011 524
2012 523
2013 546
2014 495
2015 442
2016 440
2017 440
2018 406
2019 412
2020 455
2021 501
2022 483
2023 402
2024 196

Text availability

Article attribute

Article type

Publication date

Search Results

10,861 results

Results by year

Filters applied: . Clear all
Page 1
The pharmacogenetics of treatment with olanzapine.
Zubiaur P, Soria-Chacartegui P, Villapalos-García G, Gordillo-Perdomo JJ, Abad-Santos F. Zubiaur P, et al. Pharmacogenomics. 2021 Sep;22(14):939-958. doi: 10.2217/pgs-2021-0051. Epub 2021 Sep 16. Pharmacogenomics. 2021. PMID: 34528455 Free article.
Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is associated with alterations in safety and efficacy. ...DRD2 Taq1A (rs1800497) *A1, LEP -2548 (rs7799039) G and CYP1A2*1F alleles were related to olanzapine effectiveness and sa …
Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is associated with alterations in safety and e …
Psychopharmacologic Management of Eating Disorders.
Muratore AF, Attia E. Muratore AF, et al. Curr Psychiatry Rep. 2022 Jul;24(7):345-351. doi: 10.1007/s11920-022-01340-5. Epub 2022 May 16. Curr Psychiatry Rep. 2022. PMID: 35576089 Free PMC article. Review.
The present review consolidates the most recent findings on pharmacological treatment of three eating disorders, including anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED). RECENT FINDINGS: Recent research suggests that olanzapine demonstrates p …
The present review consolidates the most recent findings on pharmacological treatment of three eating disorders, including anorexia nervosa …
Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta-analysis.
Han R, Bian Q, Chen H. Han R, et al. Brain Behav. 2022 Feb;12(2):e2498. doi: 10.1002/brb3.2498. Epub 2022 Jan 12. Brain Behav. 2022. PMID: 35020271 Free PMC article. Review.
DISCUSSION: Olanzapine showed efficacy in the treatment of AN with an increased BMI at the end of treatment in adults. The effect of olanzapine as adjuvant treatment in adolescents remains unclear....
DISCUSSION: Olanzapine showed efficacy in the treatment of AN with an increased BMI at the end of treatment in adults. The effect of …
New Antipsychotic Medications in the Last Decade.
Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. Pahwa M, et al. Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w. Curr Psychiatry Rep. 2021. PMID: 34843030 Review.
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal asenapine, …
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, …
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.
Yatham LN, Chakrabarty T, Bond DJ, Schaffer A, Beaulieu S, Parikh SV, McIntyre RS, Milev RV, Alda M, Vazquez G, Ravindran AV, Frey BN, Sharma V, Goldstein BI, Rej S, O'Donovan C, Tourjman V, Kozicky JM, Kauer-Sant'Anna M, Malhi G, Suppes T, Vieta E, Kapczinski F, Kanba S, Lam RW, Kennedy SH, Calabrese J, Berk M, Post R. Yatham LN, et al. Bipolar Disord. 2021 Dec;23(8):767-788. doi: 10.1111/bdi.13135. Epub 2021 Nov 1. Bipolar Disord. 2021. PMID: 34599629 Review.
For DSM-IV defined mixed episodes, with a longer history of research, asenapine and aripiprazole are first-line, and olanzapine (monotherapy or combination), carbamazepine, and divalproex are second-line. ...For maintenance treatment following a DSM-IV mixed episode, queti …
For DSM-IV defined mixed episodes, with a longer history of research, asenapine and aripiprazole are first-line, and olanzapine (mono …
Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.
Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Bahji A, et al. J Affect Disord. 2020 May 15;269:154-184. doi: 10.1016/j.jad.2020.03.030. Epub 2020 Mar 20. J Affect Disord. 2020. PMID: 32339131 Review.
Escitalopram, phenelzine, moclobemide, carbamazepine, sertraline, lithium, paroxetine, aripiprazole, gabapentin and ziprasidone appear to be ineffective as compared to placebo in treatment of bipolar depression. Divalproex, olanzapine/fluoxetine, olanzapine, quetiap …
Escitalopram, phenelzine, moclobemide, carbamazepine, sertraline, lithium, paroxetine, aripiprazole, gabapentin and ziprasidone appear to be …
Olanzapine/Samidorphan: First Approval.
Paik J. Paik J. Drugs. 2021 Aug;81(12):1431-1436. doi: 10.1007/s40265-021-01568-0. Drugs. 2021. PMID: 34304374 Review.
Samidorphan, which was developed by Alkermes, is an opioid receptor antagonist that has been co-formulated with olanzapine into a single-dose oral tablet to mitigate the risk of weight gain while providing the therapeutic effect of olanzapine. Olanzapine/sami …
Samidorphan, which was developed by Alkermes, is an opioid receptor antagonist that has been co-formulated with olanzapine into a sin …
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.
Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Navari RM, et al. JAMA Oncol. 2020 Jun 1;6(6):895-899. doi: 10.1001/jamaoncol.2020.1052. JAMA Oncol. 2020. PMID: 32379269 Free PMC article. Clinical Trial.
After 1 week of treatment, the reduction in nausea scores in the olanzapine arm was 8 points (95% CI, 7-8) higher than that of the placebo arm. ...One patient, on the placebo, stopped treatment early owing to lack of perceived benefit. No patients receiving olanzapine …
After 1 week of treatment, the reduction in nausea scores in the olanzapine arm was 8 points (95% CI, 7-8) higher than that of the pl …
Olanzapine-Induced Bradycardia.
Sachdeva V, Ashraf S, Inam S, Shah K, Singla A, Mansuri Z, Jain B. Sachdeva V, et al. Prim Care Companion CNS Disord. 2023 Aug 15;25(4):22cr03453. doi: 10.4088/PCC.22cr03453. Prim Care Companion CNS Disord. 2023. PMID: 37595163 Free article. No abstract available.
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.
Strawbridge R, Kurana S, Kerr-Gaffney J, Jauhar S, Kaufman KR, Yalin N, Young AH. Strawbridge R, et al. Acta Psychiatr Scand. 2022 Oct;146(4):290-311. doi: 10.1111/acps.13471. Epub 2022 Jul 20. Acta Psychiatr Scand. 2022. PMID: 35778967 Free PMC article. Review.
By assessing 95% CI overlap of within-subject efficacy effects compared to placebo, the only interventions suggesting significant depression benefits (placebo g = 0.60) were olanzapine (with/without fluoxetine; g = 1.01), citalopram (g = 1.10) and venlafaxine (g = 2.48). F …
By assessing 95% CI overlap of within-subject efficacy effects compared to placebo, the only interventions suggesting significant depression …
10,861 results
You have reached the last available page of results. Please see the User Guide for more information.